Poor
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims relate to pricing/cost and generic substitution, which are not addressed in the provided Ranexa prescribing information excerpts. None of the claims are supported or contradicted by the supplied label text, resulting in very low alignment.
Category Scores
Accurate Statements
Ranolazine is a prescription medicine used for chronic angina (chest pain).
Supported by label excerpt: “Ranexa is indicated for the treatment of chronic angina.”
Unsupported Statements
In many markets, generic ranolazine reduces cost compared with brand-name versions.
No information about generics, brand vs generic pricing, or cost comparisons appears in the provided prescribing information excerpts.
The out-of-pocket price can drop substantially when switching from a brand to a generic.
No information about out-of-pocket costs or switching effects is present in the provided label excerpts.
With insurance, patients often pay a copay or coinsurance for ranolazine.
The provided label excerpts do not discuss insurance coverage, copays, or coinsurance.
The copay or coinsurance for ranolazine can be relatively low or still high depending on the insurance plan.
No label content provided addresses variability by insurance plan or cost-sharing levels.
The out-of-pocket cost of ranolazine depends on whether ranolazine is on the patient’s formulary.
No label content provided discusses formularies or how coverage status affects cost.
Without insurance, patients pay the full retail/cash price for ranolazine.
The provided label excerpts do not address cash pricing or uninsured patient payment structure.
The cash price of ranolazine is typically much higher.
No information about cash pricing levels is included in the provided label excerpts.
Some pharmacies and discount programs can reduce cash prices for ranolazine.
No label content provided addresses discount programs, pharmacies, or price reductions.
Ranolazine pricing changes with tablet strength.
No label content provided discusses pricing by tablet strength.
Ranolazine pricing changes with the quantity of tablets in the prescription.
No label content provided discusses pricing by quantity prescribed.
Ranolazine pricing changes with formulation, including extended-release versions, if applicable in the market.
No label content provided addresses pricing differences by formulation or extended-release variants.
Ranolazine pricing changes depending on whether it is brand or generic.
No label content provided addresses brand vs generic pricing differences.
Contradictions
Important Omissions
The AI response does not provide prescribing-information-supported details for administration/dosing, which may be necessary for a dosing-related context.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are about cost/coverage rather than drug safety, dosing, contraindications, or interactions. The only supported claim is the labeled indication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Most claims are about pricing/insurance coverage and are not supported by the provided FDA-approved Ranexa prescribing information excerpts.
Suggested Improvement
Limit statements to label-supported content (e.g., indication) and avoid cost/coverage/generic pricing assertions unless the provided label excerpts explicitly address those topics.